Skip to main content
Clinical Trials/NCT04854616
NCT04854616
Completed
Not Applicable

Cessation of Smoking Trial in the Emergency Department

Norfolk and Norwich University Hospitals NHS Foundation Trust1 site in 1 country972 target enrollmentJanuary 4, 2022

Overview

Phase
Not Applicable
Intervention
CoSTED Intervention
Conditions
Smoking Cessation
Sponsor
Norfolk and Norwich University Hospitals NHS Foundation Trust
Enrollment
972
Locations
1
Primary Endpoint
Continuous smoking abstinence
Status
Completed
Last Updated
2 days ago

Overview

Brief Summary

The Cessation of Smoking Trial in the Emergency Department (CoSTED) is an National Institute for Health Research (NIHR) Health Technology Assessment (HTA) funded randomised controlled trial (RCT). The research question is "in people attending the Emergency Department who smoke, does a brief intervention (including the provision of an electronic cigarette (e-cigarette) and referral to stop smoking services) increase smoking cessation in comparison with usual care and is it cost effective?" The trial includes an internal pilot, health economic evaluation and process evaluation. The primary outcome is smoking cessation, self-reported as continuous smoking abstinence, biochemically validated by carbon monoxide monitoring with cut off of ≥8ppm. The sample size is 972 (486 in intervention and control) across 6 sites.

Detailed Description

Research question: In people attending the Emergency Department who smoke, does a brief intervention (including the provision of an e-cigarette and referral to stop smoking services) increase smoking cessation in comparison with usual care and is it cost effective? Background: Tobacco smoking is the leading cause of years of life lost in the United Kingdom (UK), and negatively impacts significantly on physical health conditions and recovery outcomes from injury or surgery. Currently, smoking prevalence is recorded at approximately 15% of the population, but this masks substantial variation between different population groups. Patient and Public Involvement (PPI) development work demonstrates that prevalence of smoking for people attending the emergency department is approximately 24%. Most current smokers will, if asked, state that they want to quit, but need support. The National Health Service (NHS) long term plan and the Tobacco control plan for England recommend smokers are supported to quit at every contact with the health service by 2023/4. To date there have been no RCTs of smoking cessation support in the Emergency Department (ED) setting in the UK, which potentially provides a highly motivating opportunistic route to intervention. Aims and objectives: To undertake an RCT, with internal pilot, comparing a brief intervention (including provision of an e-cigarette and referral to local smoking cessation services), assessing long term smoking abstinence, in people attending Emergency Departments. 1. To run an internal pilot study, with clear stop/go criteria, primarily to test recruitment systems 2. To definitively test real-world effectiveness of an ED based smoking cessation intervention in comparison with usual care, by comparing smoking abstinence at 6 month follow-up between trial groups 3. To undertake a cost effectiveness analysis of the intervention in comparison with usual care, from an NHS and personal social services (PSS) perspective 4. To undertake an embedded mixed-methods process evaluation to assess delivery, implementation, fidelity and contamination Methods: Randomised Controlled Trial of people who smoke attending an Emergency Department, with an internal pilot, health economic evaluation and process evaluation. The primary outcome is smoking cessation, self-reported as continuous smoking abstinence, biochemically validated by carbon monoxide monitoring with cut off of ≥8ppm. The sample size is 972 (with a power of 90% and a difference in quit rates between the groups of 6%). Anticipated impact and dissemination: The investigators will definitively test an ED based smoking cessation intervention and make recommendations for future implementation if effective. The intervention has the potential to reduce smoking prevalence by at least 6% based on existing evidence, impacting on improved long term health outcomes for approximately 334,000 members of the UK population if adopted across the NHS. Results will be disseminated at international conferences and published in leading journals to reach academic experts, through NHS networks and the Royal College of Emergency Medicine to reach commissioners, managers and members of the public.

Registry
clinicaltrials.gov
Start Date
January 4, 2022
End Date
September 30, 2023
Last Updated
2 days ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Adults ≥18 years old who are current daily tobacco smokers
  • Current daily tobacco smoker (self-reporting smoking of at least one cigarette per day)
  • Attending the ED for medical treatment (or accompanying a patient attending for medical treatment)
  • Submitting an expired carbon monoxide (CO) breath test reading of more than ≥8 parts per million (ppm).

Exclusion Criteria

  • Requiring immediate medical treatment as defined by the treating clinician.
  • In police custody.
  • Known history of allergy to nicotine replacement products.
  • Currently defined as dual users - already using an e-cigarette daily as well as smoking conventional cigarettes.
  • Without the capacity to give informed consent for participation in the study
  • Have taken part in the CoSTED trial already

Arms & Interventions

CoSTED Intervention

CoSTED is an opportunistic smoking cessation intervention comprising three elements: 1. brief smoking cessation advice 2. the provision of an electronic cigarette (e-cigarette) and training in its use 3. referral to stop-smoking services

Intervention: CoSTED Intervention

Treatment as Usual

Signposting to NHS smoking cessation services through provision of written information about local services.

Outcomes

Primary Outcomes

Continuous smoking abstinence

Time Frame: 6 months after randomisation

The primary outcome is smoking cessation, self-reported as continuous smoking abstinence, biochemically validated by carbon monoxide monitoring with cut off of ≥8ppm.This is according to the Russell standard, stated as: continuous abstinence (Russell Standard) \[ Time Frame: Six months post quit date \] Self-report of smoking not more than five cigarettes from the Quit date, supported by biochemical validation (expired air carbon monoxide)

Continuous Smoking Abstinence

Time Frame: 6 months after randomisation

The primary outcome is smoking cessation, self-reported as continuous smoking abstinence, biochemically validated by carbon monoxide monitoring with cut off of ≥8ppm.This is according to the Russell standard, stated as: continuous abstinence (Russell Standard) \[ Time Frame: Six months post quit date \] Self-report of smoking not more than five cigarettes from the Quit date, supported by biochemical validation (expired air carbon monoxide)

Secondary Outcomes

  • Time to relapse (if applicable)(6 months after randomisation)
  • Number of times using an e-cigarette per day(Baseline and 6 months after randomisation)
  • Motivation to stop smoking(Baseline and 6 months after randomisation)
  • Frequency of e-cigarette use in the past 6 months(6 months after randomisation)
  • Number of quit attempts(Baseline and 6 months after randomisation)
  • 7-day point prevalence abstinence(6 months after randomisation)
  • Number of cigarettes per day(Baseline and 6 months after randomisation)
  • Nicotine dependence(Baseline and 6 months after randomisation)
  • Self-reported use of healthcare services in the last 3 months(Baseline and 6 months after randomisation)
  • Adverse events(1, 3, and 6 months after randomisation)
  • Smoking status(1, 3 & 6 months after randomisation)
  • Self-reported dry cough or mouth or throat irritation(Baseline and 6 months after randomisation)
  • Self-reported use of smoking cessation services in the last 3 months(Baseline and 6 months after randomisation)
  • Quality of Life questionnaire(Baseline and 6 months after randomisation)
  • Long term follow-up 7-day point prevalence abstinence(Measured between 12 and 18 months post randomisation)
  • 7-day Point Prevalence Abstinence(6 months after randomisation)
  • Number of Quit Attempts(6 months after randomisation)
  • Number of Cigarettes Per Day(6 months after randomisation)
  • Nicotine Dependence(6 months after randomisation)
  • Number of Times Using an E-cigarette Per Day(6 months after randomisation)
  • Self-reported Dry Cough or Mouth or Throat Irritation(6 months after randomisation)
  • Motivation to Stop Smoking(6 months after randomisation)
  • Adverse Events(6 months after randomisation)
  • Smoking Status(1 month after randomisation)
  • Smoking Status at 3 Months(3 months after randomisation)
  • Smoking Status at 6 Months(6 months after randomisation)

Study Sites (1)

Loading locations...

Similar Trials